Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform technology. This application focuses exclusively on protecting the company’s advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the company’s recently announced U.S. patent application which encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain, a nasal blocker technology, and Trap and Target, designed for advanced nasal drug delivery. The T&T platform represents an advancement in intranasal drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients and addressing critical challenges in both local and systemic drug delivery.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRZ:
- Polyrizon commences GMP manufacturing process for PL-14 allergy blocker
- Polyrizon files to sell 2.42M ordinary shares for holders
- Polyrizon announces publication of patent application for hydrogel nasal tech
- Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs
- Polyrizon agreement with Eurofins secures CTM for PL-14 allergy blocker trial